Your Messages Inbox
Your Article Summary
See Latest ArticlesRegulatory update for REZONIC (casopitant mesylate)
GlaxoSmithKline, 06/24/09
GlaxoSmithKline confirmed that it has received a complete response letterfrom the FDA related to the application for casopitant. The company is reviewing this letter and will engage with the FDA to determine appropriate next steps. one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09
Review calls for EHR action in Saskatchewan
Canadian Healthcare Technology, 11/20/09
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09
Article Search
Sponsor